| Japanese |
|---|
| Title | 神経芽細胞腫における131I-MIBGシンチグラフィの臨床的検討 |
|---|
| Subtitle | 原著 |
|---|
| Authors | 岩下愼二*, 中條政敬*, 中別府良昭*, 田之上供明*, 米倉隆治*, 田口正人*, 島袋国定*, 篠原愼治*, 坂田博道** |
|---|
| Authors(kana) | |
|---|
| Organization | *鹿児島大学医学部放射線科, **福岡大学医学部放射線科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 26 |
|---|
| Number | 9 |
|---|
| Page | 1135-1147 |
|---|
| Year/Month | 1989/9 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」131I-MIBGシンチグラフィ (シンチ) を施行した神経芽細胞腫疑診例24例に検討を加えた. MIBGの陽性率は, 加療前症例で89% (8/9) , 病巣で92% (12/13) , 加療後症例で80% (8/10) , 病巣で75% (9/12) であった. また131I-MIBGシンチおよび血清NSE, 血清LDH, 尿中VMA, HVAの存在診断におけるaccuracyは加療前ではそれぞれ92% (12/13) , 80% (4/5) , 92% (11/12) , 54% (7/13) , 77% (10/13) であり, 加療後はそれぞれ88% (15/17) , 93% (13/14) , 76% (13/17) , 56% (9/16) , 56% (9/16) であった. したがって131I-MIBGシンチは神経芽細胞腫の存在・局在診断に有用であり, tumor markerとしては血清NSEが最もaccuracyが高く, 神経芽細胞腫の診断と経過観察には131I-MIBGシンチと血清NSE測定の組み合わせが最も有用と考えられた. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 131I-MIBG scintigraphy, Neuroblastoma, VMA, HVA, NSE |
|---|
| English |
|---|
| Title | Clinical Evaluation of I-131 Metaiodobenzylguanidine (MIBG) Imaging in Suspected Neuroblastoma |
|---|
| Subtitle | Original Articles |
|---|
| Authors | Shinji IWASHITA*, Masayuki NAKAJO*, Yoshiaki NAKABEPPU*, Tomoaki TANOUE*, Ryuji YONEKURA*, Masato TAGUCHI*, Kunisada SHIMABUKURO*, Shinji SHINOHARA*, Hiromichi SAKATA** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Radiology, Kagoshima University Hospital, **Department of Radiology, Fukuoka University Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 26 |
|---|
| Number | 9 |
|---|
| Page | 1135-1147 |
|---|
| Year/Month | 1989/9 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary] Twenty neuroblastoma and 4 nonneuroblastoma patients were studied by 131I-MIBG imaging. The primary tumor was detected in 89% of patients (8/9) before therapy. Bone marrow metastasis was also visualized in 4 of the 8 patients with primary positive scan. True negative results were obtained in 4 nonneuroblastoma patients. After therapy, of 10 tumor-bearing patients, eight showed positive scans and 9 of 12 lesions (75%) were visualized. The accuracies of presence or absence of neuroblastoma were compared between 131I-MIBG imaging and several tumor markers. The accuracies before and after therapy were as follows : 131I-MIBG imaging ; 92% (12/13) , 88% (15/17) , serum NSE ; 80% (4/5) , 93% (13/14) , serum LDH ; 92% (11/12) , 76% (13/17) , urinary VMA ; 54% (7/13) , 56% (9/16) , and urinary HVA ; 77% (10/13) , 56% (9/16). It appears that 131I-MIBG imaging is useful for both locating and excluding neuroblastoma. In addition, 131I-MIBG imaging appears to be the most efficient diagnostic and follow up study for neuroblastoma when it is combined with measurements of serum NSE. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 131I-MIBG scintigraphy, Neuroblastoma, VMA, HVA, NSE |
|---|